Combining TRAIL with PD1 inhibitors can effectively block the PD1/PDL1 checkpoint signals, reactivating impotent tumor-specific CD8+ T cells and initiating an immune response through immunogenic cancer cell death [100]. Here, TNFSF10 is linked to cancer.